Cosciens Biopharma (FRA:ET80) Valuation Rank


FRA:ET80 Cosciens Biopharma Inc FRA:ET80
59 GF Score
Price €7.18
GF Value €5.64
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cosciens Biopharma Valuation Rank Related Terms

FRA:ET80
59GF Score
Cosciens Biopharma Inc FRA:ET80
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cosciens Biopharma (FRA:ET80) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued. The current stock price of €7.18 is trading 27.3% above its estimated GF Value™ of €5.64. GuruFocus considers Cosciens Biopharma to be Modestly Overvalued.

Key valuation signals for FRA:ET80:

  • Valuation Rank:
  • GF Value™: €5.64 vs. price of €7.18 (27.3% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the FRA:ET80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges CSCIF:USACSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
59GF Score

Get the complete analysis for FRA:ET80

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.18
Price
€5.64
GF Value